Amarin Corp Plc (AMRN)

[drrc1949]

With enrollment for the Reduce-It Trial at 75%, it's already a huge plus for investors....although in the near term not so fortunate for enrollees. It means that overall cardiac events will really start to accelerate and begin approaching the outcomes limit. That could drag the trial's ending date forward and ultimately, the sooner results are achieved, the better for everyone. The indications on Vascepa expand for the benefit of all cardiac sufferers and as investors, we finally get a good night's sleep!